menu search

Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for t...

November 3, 2023, 10:00 am

Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting

HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...

November 1, 2023, 11:30 am

Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting

– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools –...

November 1, 2023, 10:30 am

Artios to present initial phase 1 clinical monotherapy data for atr inhibitor art0380 in advanced solid tumors at the european society of medical oncology congress 2023

ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replica...

October 5, 2023, 12:00 pm

Mink therapeutics to present data update from allogeneic inkt cells in solid tumors at sitc 2023

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discove...

September 27, 2023, 9:05 am

Relay therapeutics to present clinical data on rly-4008 in advanced fgfr2-altered solid tumors at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming...

September 18, 2023, 4:05 pm

Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 asco annual meeting

– Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools – –...

May 25, 2023, 9:05 pm

Molecular partners to present positive data from ongoing phase 1 trial of mp0317 (fap x cd40) monotherapy in patients with advanced solid tumors at the 2023 asco annual meeting

MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation...

May 25, 2023, 5:01 pm

Cullinan oncology to present first clinical data evaluating novel anti-mica/b antibody, cln-619, in patients with advanced solid tumors at asco 2023

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic...

April 26, 2023, 2:08 pm

Cullinan oncology to present first clinical data evaluating novel anti-mica/b antibody, cln-619, in patients with advanced solid tumors at asco 2023

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic...

April 26, 2023, 10:08 am

Viracta therapeutics announces preliminary dose-ranging data from the phase 1b/2 trial of nana-val in advanced epstein-barr virus-positive (ebv+) solid tumors at the esmo immuno-oncology congress

Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to d...

November 30, 2022, 11:10 pm

Masonic cancer center, university of minnesota to present data in poster presentation from the phase 1 clinical trial to evaluate hcw9218 in solid tumors at the sitc 37th annual meeting

Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HC...

November 8, 2022, 12:00 pm

Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 8, 2021, 3:10 pm

Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 8, 2021, 3:10 pm

Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 8, 2021, 3:10 pm


Search within

Pages Search Results: